Common brand names

• Poteligeo

How it is administered

Mogamulizumab is given as an intravenous (IV) infusion. This means it is delivered directly into a vein through a drip. The recommended dose is 1 mg/kg, infused over at least 60 minutes. During the first 28-day cycle, it is given on days 1, 8, 15, and 22. For subsequent cycles, it is given on days 1 and 15 of each 28-day cycle. The medication must be diluted before administration and should not be mixed with other drugs in the same IV line.

How it works

Mogamulizumab is a monoclonal antibody that specifically targets a protein called CCR4, which is found on the surface of certain cancerous T-cells and some normal immune cells. By binding to CCR4, mogamulizumab helps the immune system recognize and destroy these cancerous cells through a process called antibody-dependent cellular cytotoxicity (ADCC).

CCR4 is commonly expressed in some types of blood cancers, particularly T-cell lymphomas such as mycosis fungoides and Sézary syndrome. By depleting these cells, mogamulizumab can help control the progression of these diseases. The medication is designed to be more effective at engaging the immune system to attack the targeted cells.

Who should take it

Mogamulizumab is indicated for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), which are types of cutaneous T-cell lymphomas. It is used after at least one prior systemic therapy has been tried and was not effective or stopped working.

This medication is specifically for patients whose disease has not responded to other treatments, making it an option for those with limited alternatives. Your healthcare provider will determine if mogamulizumab is appropriate based on your specific diagnosis and treatment history.

Who should not take it

There are no absolute contraindications listed for mogamulizumab. However, caution should be used in patients with a history of autoimmune disease, as the medication can cause immune-mediated complications. It is not recommended during pregnancy or in women of childbearing potential not using contraception, as the effects on unborn babies are not fully known.

Patients who are planning to undergo allogeneic stem cell transplantation should also discuss the risks with their healthcare provider, as there is an increased risk of transplant complications if mogamulizumab is given shortly before transplantation.

Commonly used with

Mogamulizumab is typically used as a single agent for relapsed or refractory mycosis fungoides or Sézary syndrome. It is not commonly combined with other systemic therapies, especially during the initial treatment phase. However, supportive medications such as acetaminophen and diphenhydramine are often given before infusions to help prevent infusion reactions.

Commonly tested with

In clinical studies, mogamulizumab has been compared to vorinostat, another medication used for cutaneous T-cell lymphomas. Patients who did not respond to vorinostat were allowed to cross over and receive mogamulizumab. It is not typically tested in combination with other chemotherapies for blood cancers, but your healthcare team may monitor you for interactions if you are taking other medications.